Manufacturer
Amgen Biopharmaceuticals Malaysia Sdn Bhd
Contents
Filgrastim
Indication
Reduction in the duration of neutropenia & incidence of febrile neutropenia in patients treated w/ established cytotoxic chemotherapy for malignancy (w/ exception of chronic myeloid leukemia & myelodysplastic syndromes) & reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. Mobilization of peripheral blood progenitor cells (PBPC). Severe congenital, cyclic or idiopathic neutropenia & history of severe or recurrent infections. Persistent neutropenia in patients w/ advanced HIV infection.
Drug interaction
Myelosuppressive cytotoxic chemotherapeutic agents.
Amgen Biopharmaceuticals Malaysia Sdn Bhd
Contents
Filgrastim
Indication
Reduction in the duration of neutropenia & incidence of febrile neutropenia in patients treated w/ established cytotoxic chemotherapy for malignancy (w/ exception of chronic myeloid leukemia & myelodysplastic syndromes) & reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. Mobilization of peripheral blood progenitor cells (PBPC). Severe congenital, cyclic or idiopathic neutropenia & history of severe or recurrent infections. Persistent neutropenia in patients w/ advanced HIV infection.
Drug interaction
Myelosuppressive cytotoxic chemotherapeutic agents.
Inquiry - NEUPOGEN 30 MIO U 0.3MG/ML VIAL